The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Abstract
Drug development is needed to improve chemotherapy of patients with locally advanced or metastatic colon carcinoma, who otherwise have an unfavorable prognosis. DNA topoisomerase I, a nuclear enzyme important for solving topological problems arising during DNA replication and for other cellular functions, has been identified as a principal target of a plant alkaloid 20( S )-camptothecin. Significantly increased concentrations of this enzyme, compared to that in normal colonic mucosa, were found in advanced stages of human colon adenocarcinoma and in xenografts of colon cancer carried by immunodeficient mice. Several synthetic analogs of camptothecin, selected by tests with the purified enzyme and tissue-culture screens, were evaluated in the xenograft model. Unlike other anticancer drugs tested, 20( RS )-9-amino-camptothecin (9-AC) induced disease-free remissions. The overall drug toxicity was low and allowed for repeated courses of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,893
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Self-citationWall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
Self-citationDNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
Self-citationWang, J. C. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.003313 · Cited by 1,540
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
THE PROGNOSTIC SIGNIFICANCE OF DIRECT EXTENSION OF CARCINOMA OF THE COLON AND RECTUM
Astler, V. B., & Coller, F. A. (1954) · Annals of Surgery · doi:10.1097/00000658-195406000-00015 · Cited by 1,104
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Self-citationClassification of human colorectal adenocarcinoma cell lines.
Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C., & Mabry, N. D. (1976) · PubMed · Cited by 949
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Self-citation
Cited by
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
DNA Topoisomerases: Essential Enzymes and Lethal Targets
Chen, A. Y., & Liu, L. F. (1994) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.34.040194.001203 · Cited by 737
Self-citationDNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
Pommier, Y., Pourquier, P., Fan, Y., & Strumberg, D. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00129-8 · Cited by 551
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Plant-derived compounds in clinical trials
Saklani, A., & Kutty, S. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.010 · Cited by 477
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Chang, A. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.022 · Cited by 443
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Camptothecin and taxol: Discovery to clinic
Wall, M. E. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199809)18:5<299::aid-med2>3.0.co;2-o · Cited by 330
Self-citationIrinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
Topoisomerase I inhibitors: Review and update
Rothenberg, M. L. (1997) · Annals of Oncology · doi:10.1023/a:1008270717294 · Cited by 306
Lebel, M., & Leder, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13097 · Cited by 304
Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., & Rodriguez, G. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2194 · Cited by 301
Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components
Mi, Z., & Burke, T. G. (1994) · Biochemistry · doi:10.1021/bi00200a013 · Cited by 300
Camptothecins: A Review of Their Chemotherapeutic Potential
Ulukan, H., & Swaan, P. W. (2002) · Drugs · doi:10.2165/00003495-200262140-00004 · Cited by 299
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Clinical Pharmacokinetics of Irinotecan
Chabot, G. G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733040-00001 · Cited by 282
Camptothecin and taxol: from discovery to clinic
Wall, M. E., & Wani, M. C. (1996) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(95)01367-9 · Cited by 264
Self-citationTopoisomerase I inhibitors: topotecan and irenotecan
Creemers, G. J., Lund, B., & Verweij, J. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90011-6 · Cited by 252
Alkylating agents and cancer therapy
Ralhan, R., & Kaur, J. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.9.1061 · Cited by 147
Watanabe, M., Kawano, K., Yokoyama, M., Opanasopit, P., Okano, T., & Maitani, Y. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.030 · Cited by 128
Phase II study of topotecan in metastatic hormone-refractory prostate cancer
Hudes, G. R., Kosierowski, R., Greenberg, R., Ramsey, H. E., Fox, S. C., Ozols, R. F., McAleer, C. A., & Giantonio, B. J. (1995) · Investigational New Drugs · doi:10.1007/bf00873806 · Cited by 32
Metadata
- Authors
- Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M.
- Venue
- Science
- Published
- 1989-11-24
- Volume
- 246
- Issue
- 4933
- Pages
- 1046-1048
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2057409012
- Cited by
- 650
- References
- 19
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.